1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)
Jason M. Redman(National Institutes of Health), James L. Gulley(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Renee N. Donahue(National Institutes of Health), Jenn Marte(National Cancer Institute), Evrim Türkbey(National Institutes of Health Clinical Center), Lisa M. Cordes(National Institutes of Health Clinical Center), Fatima Karzai(National Institutes of Health), N. Williams(National Institute of Allergy and Infectious Diseases), Patrick Soon‐Shiong(ImmunityBio (United States)), Nicole Toney(Medpace (United States)), Jeffrey Schlom(National Cancer Institute), Amy Hankin(National Institutes of Health)
Cited by 3
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817